ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-21D12914
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Antisense oligonucleotides ASO Drug and siRNA Drug Market Research Report 2022
BUY CHAPTERS

Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Research Report 2025

Code: QYRE-Auto-21D12914
Report
July 2025
Pages:109
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Alnylam
Ionis
Biogen
Novartis
Sarepta Therapeutics
Therapeutics
Akcea
WAVElife
ProQR
Exicure Inc
Secarna
Astrazeneca plc
The WhiteOak Group, Inc.
Dicerna
Silence
Arrowhead
miRagen Therapeutics
Genzyme
Quark Pharmaceuticals
Sylentis
Avidity Biosciences
Novo Nordisk
Sirnaomics

Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size

The global market for Antisense oligonucleotides (ASO) Drug and siRNA Drug was valued at US$ 3192 million in the year 2024 and is projected to reach a revised size of US$ 11332 million by 2031, growing at a CAGR of 23.0% during the forecast period.

Antisense oligonucleotides (ASO) Drug and siRNA Drug Market

Antisense oligonucleotides (ASO) Drug and siRNA Drug Market

Small nucleic acid drugs are short in length and have a base of less than 30 nt. They mainly act on mRNA in cells through the principle of complementary base pairing to regulate protein expression, thereby achieving therapeutic effects. It can be further divided into single-stranded antisense oligonucleotide ASO, and double-stranded nucleotide siRNA.
The main market drivers of antisense oligonucleotide (ASO) drugs and siRNA drugs include the following:
1. Technological breakthrough: the leap from laboratory to clinic
Technological evolution of ASO drugs
Chemical modification and delivery system optimization: The first generation of ASO drugs were limited by poor stability and high immunogenicity. The third generation of ASO significantly improved the resistance to nucleases and pharmacokinetic properties through thiophosphate backbone modification, glycosylation modification and other technologies. For example, Ionis' Eplontersen uses ligand coupling technology to achieve subcutaneous administration once a month, which greatly improves patient compliance.
Indication expansion: ASO drugs extend from genetic diseases (such as Duchenne muscular dystrophy) to tumors and metabolic diseases. Geron's Imetelstat was approved as the first telomerase inhibitor, providing a new treatment for myelodysplastic syndrome.
Technological revolution of siRNA drugs
Delivery system breakthrough: In 2014, the GalNAc ligand technology came into being, solving the problem of liver targeting and promoting Alnylam's Onpattro (approved in 2018) to become the first siRNA drug. Current research focuses on multi-organ delivery, such as Alnylam's mivelsiran (Phase II for cerebral amyloid angiopathy) and Arrowhead's ARO-RAGE (Phase I for asthma), which achieve cross-blood-brain barrier targeting through lipid nanoparticles (LNP) or antibody coupling.
Advantages of long-term efficacy and reversibility: siRNA drugs such as Inclisiran (lipid-lowering) can be administered once every six months, and the effect is reversible, avoiding the permanent risk of gene editing.
2. Policy support: Catalyst for the global innovative drug ecosystem
Regulatory approval acceleration
The FDA accelerates the approval of small nucleic acid drugs through mechanisms such as "fast track" and "breakthrough therapy". For example, Eplontersen took only 3 years from clinical to approval, which is far lower than the 10-year cycle of traditional drugs.
China's "14th Five-Year Plan for the Development of the Pharmaceutical Industry" clearly supports the development of new delivery systems, optimizes the review process, and promotes ASO/siRNA drugs into clinical trials.
Medical insurance coverage and payment innovation
European and American medical insurance explores the "pay-by-efficacy" model for high-priced small nucleic acid drugs (such as Onpattro, which costs about $450,000 per year) to reduce the burden on patients.
China is incorporating drugs for rare diseases into medical insurance negotiations. The ASO drug Spinraza (nusinersen) has been negotiated to reduce its price, and its accessibility has been improved.
3. Market demand: a blue ocean with unmet clinical needs
Genetic diseases and rare diseases
ASO drugs dominate the field of spinal muscular atrophy (SMA), with global sales of Spinraza exceeding US$2 billion. siRNA drugs such as Amvuttra (transthyretin amyloidosis) fill the gap in the treatment of genetic diseases.
There are more than 300 million patients with rare diseases worldwide, but approved drugs only cover 5%, and the market potential is huge.
Expansion of chronic and metabolic diseases
The siRNA drug Inclisiran has expanded its indications from familial hypercholesterolemia to atherosclerotic cardiovascular disease, and the patient population has expanded 10 times.
In the field of metabolic-associated fatty hepatitis (MASH), Alnylam's Lundquist and other siRNA drugs have entered Phase III clinical trials, and the market size is expected to exceed US$35 billion in 2030.
IV. Capital investment: the "fuel" for innovative drug research and development
Venture capital and IPO are active
In 2023, there will be 31 transactions in the global small nucleic acid field, with a total amount of US$8.496 billion (up 371% year-on-year). China Jingyin Pharmaceutical completed nearly US$50 million in B2 round financing to accelerate the development of cardiovascular siRNA pipeline.
In 2024, Boehringer Ingelheim and Ribo Bio reached a US$2 billion cooperation to develop siRNA drugs for MASH.
The layout of multinational pharmaceutical companies is accelerating
AstraZeneca introduced Ionis's Eplontersen for US$3.585 billion to expand the field of heart failure; Novartis consolidated the cardiovascular market through Leqvio (lipid-lowering siRNA).
In 2025, GSK acquired Boston Pharmaceuticals' FGF21 siRNA project for US$1.2 billion, betting on metabolic diseases.
5. Competition landscape: Evolution from "unipolar" to "multipolar"
Monopoly and breakthroughs of international giants
Ionis (ASO) and Alnylam (siRNA) occupy the main global market share, but newcomers such as Arrowhead and Dicerna challenge the leading position through differentiated technologies (such as multi-organ delivery).
Eli Lilly cooperates with Alnylam to develop siRNA drugs for Alzheimer's disease, using its delivery technology to break through the blood-brain barrier.
The rise of Chinese companies
Domestic ASO field: Ruibo Bio and Yuekang Pharmaceuticals advance clinical pipelines through cooperative development, but no self-developed products have been launched.
siRNA field: Many drugs of Shengyin Bio and Bowang Pharmaceutical have entered Phase I, targeting common diseases such as hypertension and hyperlipidemia, filling the domestic gap.
6. Challenges and future trends
Technical bottlenecks to be broken through
The off-target effects and immunogenicity of ASO drugs still need to be optimized; the kidney and lung delivery efficiency of siRNA is low, which limits the expansion of indications.
Competitive pressure from gene editing technologies (such as CRISPR): Verve Therapeutics' PCSK9 gene editing therapy has entered clinical trials and may replace part of the siRNA market.
Driven by policy support and capital, the growth rate of the Chinese market will be higher than the global average, and ASO/siRNA drugs are expected to become the core track of the "new infrastructure" of biomedicine.
The market explosion of ASO and siRNA drugs is the result of the resonance of technological breakthroughs, policy dividends, capital catalysis and unmet needs. In the future, with the innovation of delivery systems and the expansion of multiple indications, small nucleic acid drugs will move from "niche genetic diseases" to "mass chronic diseases", reshaping the global pharmaceutical landscape.
This report aims to provide a comprehensive presentation of the global market for Antisense oligonucleotides (ASO) Drug and siRNA Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antisense oligonucleotides (ASO) Drug and siRNA Drug.
The Antisense oligonucleotides (ASO) Drug and siRNA Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antisense oligonucleotides (ASO) Drug and siRNA Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antisense oligonucleotides (ASO) Drug and siRNA Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Report

Report Metric Details
Report Name Antisense oligonucleotides (ASO) Drug and siRNA Drug Market
Accounted market size in year US$ 3192 million
Forecasted market size in 2031 US$ 11332 million
CAGR 23.0%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Antisense Oligonucleotides (ASO) Drug
  • siRNA Drug
Segment by Application
  • Single Gene Rare Disease
  • Protein Deposition Disease
  • Chronic Liver Disease
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Alnylam, Ionis, Biogen, Novartis, Sarepta Therapeutics, Therapeutics, Akcea, WAVElife, ProQR, Exicure, Secarna, AstraZeneca, The WhiteOak Group, Inc., Dicerna, Silence, Arrowhead, Miragen Therapeutics, Genzyme, Quark Pharmaceuticals, Sylentis, Avidity Biosciences, Novo Nordisk, Sirnaomics
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Antisense oligonucleotides (ASO) Drug and siRNA Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Antisense oligonucleotides (ASO) Drug and siRNA Drug Market growing?

Ans: The Antisense oligonucleotides (ASO) Drug and siRNA Drug Market witnessing a CAGR of 23.0% during the forecast period 2025-2031.

What is the Antisense oligonucleotides (ASO) Drug and siRNA Drug Market size in 2031?

Ans: The Antisense oligonucleotides (ASO) Drug and siRNA Drug Market size in 2031 will be US$ 11332 million.

Who are the main players in the Antisense oligonucleotides (ASO) Drug and siRNA Drug Market report?

Ans: The main players in the Antisense oligonucleotides (ASO) Drug and siRNA Drug Market are Alnylam, Ionis, Biogen, Novartis, Sarepta Therapeutics, Therapeutics, Akcea, WAVElife, ProQR, Exicure, Secarna, AstraZeneca, The WhiteOak Group, Inc., Dicerna, Silence, Arrowhead, Miragen Therapeutics, Genzyme, Quark Pharmaceuticals, Sylentis, Avidity Biosciences, Novo Nordisk, Sirnaomics

What are the Application segmentation covered in the Antisense oligonucleotides (ASO) Drug and siRNA Drug Market report?

Ans: The Applications covered in the Antisense oligonucleotides (ASO) Drug and siRNA Drug Market report are Single Gene Rare Disease, Protein Deposition Disease, Chronic Liver Disease, Others

What are the Type segmentation covered in the Antisense oligonucleotides (ASO) Drug and siRNA Drug Market report?

Ans: The Types covered in the Antisense oligonucleotides (ASO) Drug and siRNA Drug Market report are Antisense Oligonucleotides (ASO) Drug, siRNA Drug

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Antisense Oligonucleotides (ASO) Drug
1.2.3 siRNA Drug
1.3 Market by Application
1.3.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Single Gene Rare Disease
1.3.3 Protein Deposition Disease
1.3.4 Chronic Liver Disease
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Perspective (2020-2031)
2.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Growth Trends by Region
2.2.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Antisense oligonucleotides (ASO) Drug and siRNA Drug Historic Market Size by Region (2020-2025)
2.2.3 Antisense oligonucleotides (ASO) Drug and siRNA Drug Forecasted Market Size by Region (2026-2031)
2.3 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Dynamics
2.3.1 Antisense oligonucleotides (ASO) Drug and siRNA Drug Industry Trends
2.3.2 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Drivers
2.3.3 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Challenges
2.3.4 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antisense oligonucleotides (ASO) Drug and siRNA Drug Players by Revenue
3.1.1 Global Top Antisense oligonucleotides (ASO) Drug and siRNA Drug Players by Revenue (2020-2025)
3.1.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Players (2020-2025)
3.2 Global Top Antisense oligonucleotides (ASO) Drug and siRNA Drug Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue
3.4 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Concentration Ratio
3.4.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue in 2024
3.5 Global Key Players of Antisense oligonucleotides (ASO) Drug and siRNA Drug Head office and Area Served
3.6 Global Key Players of Antisense oligonucleotides (ASO) Drug and siRNA Drug, Product and Application
3.7 Global Key Players of Antisense oligonucleotides (ASO) Drug and siRNA Drug, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Antisense oligonucleotides (ASO) Drug and siRNA Drug Breakdown Data by Type
4.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Historic Market Size by Type (2020-2025)
4.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Forecasted Market Size by Type (2026-2031)
5 Antisense oligonucleotides (ASO) Drug and siRNA Drug Breakdown Data by Application
5.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Historic Market Size by Application (2020-2025)
5.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (2020-2031)
6.2 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2020-2025)
6.4 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (2020-2031)
7.2 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2020-2025)
7.4 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (2020-2031)
8.2 Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (2020-2025)
8.4 Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (2020-2031)
9.2 Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2020-2025)
9.4 Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (2020-2031)
10.2 Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2020-2025)
10.4 Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Alnylam
11.1.1 Alnylam Company Details
11.1.2 Alnylam Business Overview
11.1.3 Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Introduction
11.1.4 Alnylam Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
11.1.5 Alnylam Recent Development
11.2 Ionis
11.2.1 Ionis Company Details
11.2.2 Ionis Business Overview
11.2.3 Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Introduction
11.2.4 Ionis Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
11.2.5 Ionis Recent Development
11.3 Biogen
11.3.1 Biogen Company Details
11.3.2 Biogen Business Overview
11.3.3 Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Introduction
11.3.4 Biogen Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
11.3.5 Biogen Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Introduction
11.4.4 Novartis Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
11.4.5 Novartis Recent Development
11.5 Sarepta Therapeutics
11.5.1 Sarepta Therapeutics Company Details
11.5.2 Sarepta Therapeutics Business Overview
11.5.3 Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Introduction
11.5.4 Sarepta Therapeutics Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
11.5.5 Sarepta Therapeutics Recent Development
11.6 Therapeutics
11.6.1 Therapeutics Company Details
11.6.2 Therapeutics Business Overview
11.6.3 Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Introduction
11.6.4 Therapeutics Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
11.6.5 Therapeutics Recent Development
11.7 Akcea
11.7.1 Akcea Company Details
11.7.2 Akcea Business Overview
11.7.3 Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Introduction
11.7.4 Akcea Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
11.7.5 Akcea Recent Development
11.8 WAVElife
11.8.1 WAVElife Company Details
11.8.2 WAVElife Business Overview
11.8.3 WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Introduction
11.8.4 WAVElife Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
11.8.5 WAVElife Recent Development
11.9 ProQR
11.9.1 ProQR Company Details
11.9.2 ProQR Business Overview
11.9.3 ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Introduction
11.9.4 ProQR Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
11.9.5 ProQR Recent Development
11.10 Exicure
11.10.1 Exicure Company Details
11.10.2 Exicure Business Overview
11.10.3 Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Introduction
11.10.4 Exicure Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
11.10.5 Exicure Recent Development
11.11 Secarna
11.11.1 Secarna Company Details
11.11.2 Secarna Business Overview
11.11.3 Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Introduction
11.11.4 Secarna Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
11.11.5 Secarna Recent Development
11.12 AstraZeneca
11.12.1 AstraZeneca Company Details
11.12.2 AstraZeneca Business Overview
11.12.3 AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Introduction
11.12.4 AstraZeneca Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
11.12.5 AstraZeneca Recent Development
11.13 The WhiteOak Group, Inc.
11.13.1 The WhiteOak Group, Inc. Company Details
11.13.2 The WhiteOak Group, Inc. Business Overview
11.13.3 The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Introduction
11.13.4 The WhiteOak Group, Inc. Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
11.13.5 The WhiteOak Group, Inc. Recent Development
11.14 Dicerna
11.14.1 Dicerna Company Details
11.14.2 Dicerna Business Overview
11.14.3 Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Introduction
11.14.4 Dicerna Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
11.14.5 Dicerna Recent Development
11.15 Silence
11.15.1 Silence Company Details
11.15.2 Silence Business Overview
11.15.3 Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Introduction
11.15.4 Silence Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
11.15.5 Silence Recent Development
11.16 Arrowhead
11.16.1 Arrowhead Company Details
11.16.2 Arrowhead Business Overview
11.16.3 Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Introduction
11.16.4 Arrowhead Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
11.16.5 Arrowhead Recent Development
11.17 Miragen Therapeutics
11.17.1 Miragen Therapeutics Company Details
11.17.2 Miragen Therapeutics Business Overview
11.17.3 Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Introduction
11.17.4 Miragen Therapeutics Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
11.17.5 Miragen Therapeutics Recent Development
11.18 Genzyme
11.18.1 Genzyme Company Details
11.18.2 Genzyme Business Overview
11.18.3 Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Introduction
11.18.4 Genzyme Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
11.18.5 Genzyme Recent Development
11.19 Quark Pharmaceuticals
11.19.1 Quark Pharmaceuticals Company Details
11.19.2 Quark Pharmaceuticals Business Overview
11.19.3 Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Introduction
11.19.4 Quark Pharmaceuticals Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
11.19.5 Quark Pharmaceuticals Recent Development
11.20 Sylentis
11.20.1 Sylentis Company Details
11.20.2 Sylentis Business Overview
11.20.3 Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Introduction
11.20.4 Sylentis Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
11.20.5 Sylentis Recent Development
11.21 Avidity Biosciences
11.21.1 Avidity Biosciences Company Details
11.21.2 Avidity Biosciences Business Overview
11.21.3 Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Introduction
11.21.4 Avidity Biosciences Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
11.21.5 Avidity Biosciences Recent Development
11.22 Novo Nordisk
11.22.1 Novo Nordisk Company Details
11.22.2 Novo Nordisk Business Overview
11.22.3 Novo Nordisk Antisense oligonucleotides (ASO) Drug and siRNA Drug Introduction
11.22.4 Novo Nordisk Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
11.22.5 Novo Nordisk Recent Development
11.23 Sirnaomics
11.23.1 Sirnaomics Company Details
11.23.2 Sirnaomics Business Overview
11.23.3 Sirnaomics Antisense oligonucleotides (ASO) Drug and siRNA Drug Introduction
11.23.4 Sirnaomics Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
11.23.5 Sirnaomics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Alnylam
Ionis
Biogen
Novartis
Sarepta Therapeutics
Therapeutics
Akcea
WAVElife
ProQR
Exicure Inc
Secarna
Astrazeneca plc
The WhiteOak Group, Inc.
Dicerna
Silence
Arrowhead
miRagen Therapeutics
Genzyme
Quark Pharmaceuticals
Sylentis
Avidity Biosciences
Novo Nordisk
Sirnaomics
List of Tables
 Table 1. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Antisense Oligonucleotides (ASO) Drug
 Table 3. Key Players of siRNA Drug
 Table 4. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 5. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (2020-2025) & (US$ Million)
 Table 7. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Region (2020-2025)
 Table 8. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 9. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Region (2026-2031)
 Table 10. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Trends
 Table 11. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Drivers
 Table 12. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Challenges
 Table 13. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Restraints
 Table 14. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Players (2020-2025) & (US$ Million)
 Table 15. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Players (2020-2025)
 Table 16. Global Top Antisense oligonucleotides (ASO) Drug and siRNA Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug as of 2024)
 Table 17. Ranking of Global Top Antisense oligonucleotides (ASO) Drug and siRNA Drug Companies by Revenue (US$ Million) in 2024
 Table 18. Global 5 Largest Players Market Share by Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue (CR5 and HHI) & (2020-2025)
 Table 19. Global Key Players of Antisense oligonucleotides (ASO) Drug and siRNA Drug, Headquarters and Area Served
 Table 20. Global Key Players of Antisense oligonucleotides (ASO) Drug and siRNA Drug, Product and Application
 Table 21. Global Key Players of Antisense oligonucleotides (ASO) Drug and siRNA Drug, Date of Enter into This Industry
 Table 22. Mergers & Acquisitions, Expansion Plans
 Table 23. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Type (2020-2025) & (US$ Million)
 Table 24. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Type (2020-2025)
 Table 25. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 26. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Type (2026-2031)
 Table 27. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Application (2020-2025) & (US$ Million)
 Table 28. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Application (2020-2025)
 Table 29. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 30. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue Market Share by Application (2026-2031)
 Table 31. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 32. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2020-2025) & (US$ Million)
 Table 33. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2026-2031) & (US$ Million)
 Table 34. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2020-2025) & (US$ Million)
 Table 36. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (2020-2025) & (US$ Million)
 Table 39. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2020-2025) & (US$ Million)
 Table 42. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2026-2031) & (US$ Million)
 Table 43. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Alnylam Company Details
 Table 47. Alnylam Business Overview
 Table 48. Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
 Table 49. Alnylam Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025) & (US$ Million)
 Table 50. Alnylam Recent Development
 Table 51. Ionis Company Details
 Table 52. Ionis Business Overview
 Table 53. Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
 Table 54. Ionis Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025) & (US$ Million)
 Table 55. Ionis Recent Development
 Table 56. Biogen Company Details
 Table 57. Biogen Business Overview
 Table 58. Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
 Table 59. Biogen Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025) & (US$ Million)
 Table 60. Biogen Recent Development
 Table 61. Novartis Company Details
 Table 62. Novartis Business Overview
 Table 63. Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
 Table 64. Novartis Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025) & (US$ Million)
 Table 65. Novartis Recent Development
 Table 66. Sarepta Therapeutics Company Details
 Table 67. Sarepta Therapeutics Business Overview
 Table 68. Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
 Table 69. Sarepta Therapeutics Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025) & (US$ Million)
 Table 70. Sarepta Therapeutics Recent Development
 Table 71. Therapeutics Company Details
 Table 72. Therapeutics Business Overview
 Table 73. Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
 Table 74. Therapeutics Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025) & (US$ Million)
 Table 75. Therapeutics Recent Development
 Table 76. Akcea Company Details
 Table 77. Akcea Business Overview
 Table 78. Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
 Table 79. Akcea Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025) & (US$ Million)
 Table 80. Akcea Recent Development
 Table 81. WAVElife Company Details
 Table 82. WAVElife Business Overview
 Table 83. WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
 Table 84. WAVElife Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025) & (US$ Million)
 Table 85. WAVElife Recent Development
 Table 86. ProQR Company Details
 Table 87. ProQR Business Overview
 Table 88. ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
 Table 89. ProQR Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025) & (US$ Million)
 Table 90. ProQR Recent Development
 Table 91. Exicure Company Details
 Table 92. Exicure Business Overview
 Table 93. Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
 Table 94. Exicure Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025) & (US$ Million)
 Table 95. Exicure Recent Development
 Table 96. Secarna Company Details
 Table 97. Secarna Business Overview
 Table 98. Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
 Table 99. Secarna Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025) & (US$ Million)
 Table 100. Secarna Recent Development
 Table 101. AstraZeneca Company Details
 Table 102. AstraZeneca Business Overview
 Table 103. AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
 Table 104. AstraZeneca Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025) & (US$ Million)
 Table 105. AstraZeneca Recent Development
 Table 106. The WhiteOak Group, Inc. Company Details
 Table 107. The WhiteOak Group, Inc. Business Overview
 Table 108. The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
 Table 109. The WhiteOak Group, Inc. Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025) & (US$ Million)
 Table 110. The WhiteOak Group, Inc. Recent Development
 Table 111. Dicerna Company Details
 Table 112. Dicerna Business Overview
 Table 113. Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
 Table 114. Dicerna Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025) & (US$ Million)
 Table 115. Dicerna Recent Development
 Table 116. Silence Company Details
 Table 117. Silence Business Overview
 Table 118. Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
 Table 119. Silence Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025) & (US$ Million)
 Table 120. Silence Recent Development
 Table 121. Arrowhead Company Details
 Table 122. Arrowhead Business Overview
 Table 123. Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
 Table 124. Arrowhead Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025) & (US$ Million)
 Table 125. Arrowhead Recent Development
 Table 126. Miragen Therapeutics Company Details
 Table 127. Miragen Therapeutics Business Overview
 Table 128. Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
 Table 129. Miragen Therapeutics Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025) & (US$ Million)
 Table 130. Miragen Therapeutics Recent Development
 Table 131. Genzyme Company Details
 Table 132. Genzyme Business Overview
 Table 133. Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
 Table 134. Genzyme Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025) & (US$ Million)
 Table 135. Genzyme Recent Development
 Table 136. Quark Pharmaceuticals Company Details
 Table 137. Quark Pharmaceuticals Business Overview
 Table 138. Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
 Table 139. Quark Pharmaceuticals Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025) & (US$ Million)
 Table 140. Quark Pharmaceuticals Recent Development
 Table 141. Sylentis Company Details
 Table 142. Sylentis Business Overview
 Table 143. Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
 Table 144. Sylentis Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025) & (US$ Million)
 Table 145. Sylentis Recent Development
 Table 146. Avidity Biosciences Company Details
 Table 147. Avidity Biosciences Business Overview
 Table 148. Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
 Table 149. Avidity Biosciences Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025) & (US$ Million)
 Table 150. Avidity Biosciences Recent Development
 Table 151. Novo Nordisk Company Details
 Table 152. Novo Nordisk Business Overview
 Table 153. Novo Nordisk Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
 Table 154. Novo Nordisk Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025) & (US$ Million)
 Table 155. Novo Nordisk Recent Development
 Table 156. Sirnaomics Company Details
 Table 157. Sirnaomics Business Overview
 Table 158. Sirnaomics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product
 Table 159. Sirnaomics Revenue in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025) & (US$ Million)
 Table 160. Sirnaomics Recent Development
 Table 161. Research Programs/Design for This Report
 Table 162. Key Data Information from Secondary Sources
 Table 163. Key Data Information from Primary Sources
 Table 164. Authors List of This Report


List of Figures
 Figure 1. Antisense oligonucleotides (ASO) Drug and siRNA Drug Picture
 Figure 2. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Type: 2024 VS 2031
 Figure 4. Antisense Oligonucleotides (ASO) Drug Features
 Figure 5. siRNA Drug Features
 Figure 6. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Application (2020-2031) & (US$ Million)
 Figure 7. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Application: 2024 VS 2031
 Figure 8. Single Gene Rare Disease Case Studies
 Figure 9. Protein Deposition Disease Case Studies
 Figure 10. Chronic Liver Disease Case Studies
 Figure 11. Others Case Studies
 Figure 12. Antisense oligonucleotides (ASO) Drug and siRNA Drug Report Years Considered
 Figure 13. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 14. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Region: 2024 VS 2031
 Figure 16. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Players in 2024
 Figure 17. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 18. The Top 10 and 5 Players Market Share by Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue in 2024
 Figure 19. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 20. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Country (2020-2031)
 Figure 21. United States Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Country (2020-2031)
 Figure 25. Germany Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. France Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. U.K. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Italy Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Russia Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Ireland Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Region (2020-2031)
 Figure 33. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Japan Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. South Korea Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Southeast Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. India Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Australia & New Zealand Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Country (2020-2031)
 Figure 41. Mexico Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Brazil Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Share by Country (2020-2031)
 Figure 45. Israel Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Saudi Arabia Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. UAE Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Alnylam Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
 Figure 49. Ionis Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
 Figure 50. Biogen Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
 Figure 51. Novartis Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
 Figure 52. Sarepta Therapeutics Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
 Figure 53. Therapeutics Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
 Figure 54. Akcea Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
 Figure 55. WAVElife Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
 Figure 56. ProQR Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
 Figure 57. Exicure Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
 Figure 58. Secarna Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
 Figure 59. AstraZeneca Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
 Figure 60. The WhiteOak Group, Inc. Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
 Figure 61. Dicerna Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
 Figure 62. Silence Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
 Figure 63. Arrowhead Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
 Figure 64. Miragen Therapeutics Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
 Figure 65. Genzyme Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
 Figure 66. Quark Pharmaceuticals Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
 Figure 67. Sylentis Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
 Figure 68. Avidity Biosciences Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
 Figure 69. Novo Nordisk Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
 Figure 70. Sirnaomics Revenue Growth Rate in Antisense oligonucleotides (ASO) Drug and siRNA Drug Business (2020-2025)
 Figure 71. Bottom-up and Top-down Approaches for This Report
 Figure 72. Data Triangulation
 Figure 73. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

Global Antisense Oligonucleotides ASO Drug Market Research Report 2024
Antisense Oligonucleotide ASO Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Antisense Oligonucleotide Service Market Research Report 2025
Global Antisense Oligonucleotides ASOs Drugs Market Research Report 2024
Global Antisense Oligonucleotides ASO Therapy Market Research Report 2024
Global ASO based Drug Market Research Report 2024
Global siRNA Drug Market Research Report 2024
Global Antisense Oligonucleotides based Therapeutics Market Research Report 2024
Global Antisense Oligonucleotides Market Research Report 2024
Global Antisense Oligonucleotide Therapy for the Nervous System Market Research Report 2024
Global Antisense ODN Market Research Report 2024
Global Oligonucleotide Drugs ONs Market Research Report 2025
Global Antisense and RNA Interference Therapeutics Market Research Report 2024
Antisense and RNAi Therapeutics Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Small Nucleic Acid Drug Market Research Report 2025
Global siRNA Drugs Market Research Report 2024
Global Antisense Therapy Market Research Report 2024
Global Nucleic Acid Drugs Market Research Report 2025
Global Low Molecular Weight Nucleic Acid Drugs Market Research Report 2025
Global Small Interfering RNA siRNA Drugs Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions